Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 28,867,487	$ 18,676,663
Contracts and grants receivable	44,184	203,774
Research and development incentives receivable	103,773	361,096
Prepaid expenses and other current assets	429,094	225,473
Total current assets	29,444,538	19,467,006
Security deposit	22,777	22,777
Office furniture and equipment, net of accumulated depreciation of $164,176 and $154,769	14,103	23,510
Deferred issuance cost	20,651	53,523
Right-of-use lease assets	136,321	228,027
Research and development incentive receivable	67,782	73,142
Other assets	11,626	23,250
Total assets	29,717,798	19,891,235
Current liabilities:
Accounts payable	1,905,779	2,129,844
Accrued expenses	2,716,745	2,638,308
Accrued compensation	58,729	875,096
Paycheck Protection Program loan		324,979
Lease liabilities - current	114,377	112,294
Total current liabilities	4,795,630	6,080,521
Non-current liabilities:
Convertible debt, net of debt discount of $154,317 and $140,261	9,845,683	9,859,739
Paycheck Protection Program loan, net of current		92,851
Lease liabilities, net of current	21,942	116,296
Total liabilities	14,663,255	16,149,407
Commitments and contingencies
Shareholders' equity:
Preferred stock, 350,000 shares authorized, none issued or outstanding
Common stock, $.001 par value; 75,000,000 shares authorized; 42,630,436 shares and 30,643,656 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	42,630	30,644
Additional paid-in capital	216,023,586	196,949,655
Accumulated other comprehensive income (loss)	49,558	(24,337)
Accumulated deficit	(201,061,231)	(193,214,134)
Total shareholders' equity	15,054,543	3,741,828
Total liabilities and shareholders' equity	$ 29,717,798	$ 19,891,235